Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Immunotherapy
Findings from Uppsala University advance knowledge in breast cancer immunotherapy
April 11th, 2007
A report, "Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy," is newly published data in The Prostate. According to a study from Uppsala, Sweden, "In order to develop experimental immunotherapy for prostate and breast cancer it is of outmost importance to have representative target cell lines that through human leukocyte antigen (HLA) class I molecules present relevant levels of peptides from tumor-associated antigens for cytotoxic T lymphocyte (CTL) recognition. We sequenced the HLA-A and HLA-B loci of eight commonly used prostate and breast cancer cell lines and analyzed the surface expression of HLA-ABC, HLA-DR, CD40,...
Source: Immunotherapy Weekly (2007-04-11)
|
